Your prediction
Amphastar Pharmaceuticals Inc Stock
Pros and Cons of Amphastar Pharmaceuticals Inc in the next few years
Pros
Cons
Performance of Amphastar Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 3.010% | 3.033% | -2.066% | -0.026% | -32.053% | - | - |
| Rockwell Medical Inc. | 2.380% | -6.480% | 9.890% | -28.205% | -21.437% | -84.031% | -96.909% |
| Gritstone Oncology Inc | 0.210% | -18.757% | -69.521% | -70.915% | -62.352% | -90.305% | - |
| Innoviva Inc. | 0.740% | 0.730% | 2.985% | 32.692% | -5.479% | 40.102% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Amphastar Pharms, a player in the pharmaceutical industry, showcases financials that merit a multifaceted analysis to grasp the full picture. At first glance, the growth in total assets and stockholder equity over the last three years paints a picture of a company that’s fortifying its balance sheet and increasing shareholder value. This premise, supported by consistent net income growth as evidenced in the income statements, hints at a robust foundation for future growth. However, a deep dive into the particulars of its financial statements coupled with the financial ratios is essential to evaluate the company's true financial health and potential.
*Pros: *
Revenue Growth: With a quarterly revenue growth year-over-year (YOY) of 50.3%, Amphastar Pharms is on a positive trajectory, outstripping many competitors in the pharmaceutical field.